Lilly's Heavyweight Weight Loss Drug Approved to Compete head-on with Novo Nordisk
海角七号
发表于 2023-11-9 19:47:44
273
0
0
On November 8th, the US FDA approved Lilly's Tirzepatide for weight loss indications (trade name: Zepbound), becoming another approved weight loss drug after Novo Nordisk's Wegovy and paving the way for its wider use.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Interest rate hike is approaching! The Bank of Japan has just issued a heavy signal!
- Multiple new indications for Merck drugs approved for market in China
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Novo Nordisk's pre-market decline narrows to 20%
- BeiGene and BeiZeAn are approved for new indications in the United States
